| Released | Contributor | Author | Title | Pages | Price |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | 3SBIO INC (SSRX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | 3SBIO INC (SSRX=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for SSRX. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 23-Nov-2009 | Zacks Investment Research Inc. |
N/A
| 3SBIO INC-ADS (SSRX) Zacks Company Snapshot | 1 |
$10 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Trends, Statistics & Analysis 2010 (Summary) | 98 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Plunkett's Health Care Technologies Overview 2010 (Summary) | 80 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Market Research and Competitive Analysis 2010 | 730 |
$299 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for SSRX | 13 |
$25 |
1.48% Nasdaq 
0.45 (3.32%) 
Research Reports
